271 related articles for article (PubMed ID: 10362790)
21. t(1;2)(q21;p23) and t(2;3)(p23;q21): two novel variant translocations of the t(2;5)(p23;q35) in anaplastic large cell lymphoma.
Rosenwald A; Ott G; Pulford K; Katzenberger T; Kühl J; Kalla J; Ott MM; Mason DY; Müller-Hermelink HK
Blood; 1999 Jul; 94(1):362-4. PubMed ID: 10381534
[TBL] [Abstract][Full Text] [Related]
22. The NPM-ALK and the ATIC-ALK fusion genes can be detected in non-neoplastic cells.
Maes B; Vanhentenrijk V; Wlodarska I; Cools J; Peeters B; Marynen P; de Wolf-Peeters C
Am J Pathol; 2001 Jun; 158(6):2185-93. PubMed ID: 11395396
[TBL] [Abstract][Full Text] [Related]
23. Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma.
Sjostrom C; Seiler C; Crockett DK; Tripp SR; Elenitoba Johnson KS; Lim MS
Exp Hematol; 2007 Aug; 35(8):1240-8. PubMed ID: 17560012
[TBL] [Abstract][Full Text] [Related]
24. Inv(2)(p23q35) in anaplastic large-cell lymphoma induces constitutive anaplastic lymphoma kinase (ALK) tyrosine kinase activation by fusion to ATIC, an enzyme involved in purine nucleotide biosynthesis.
Ma Z; Cools J; Marynen P; Cui X; Siebert R; Gesk S; Schlegelberger B; Peeters B; De Wolf-Peeters C; Wlodarska I; Morris SW
Blood; 2000 Mar; 95(6):2144-9. PubMed ID: 10706887
[TBL] [Abstract][Full Text] [Related]
25. Nucleolar localization of the nucleophosmin-anaplastic lymphoma kinase is not required for malignant transformation.
Mason DY; Pulford KA; Bischof D; Kuefer MU; Butler LH; Lamant L; Delsol G; Morris SW
Cancer Res; 1998 Mar; 58(5):1057-62. PubMed ID: 9500471
[TBL] [Abstract][Full Text] [Related]
26. The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.
Dirks WG; Zaborski M; Jäger K; Challier C; Shiota M; Quentmeier H; Drexler HG
Leukemia; 1996 Jan; 10(1):142-9. PubMed ID: 8558920
[TBL] [Abstract][Full Text] [Related]
27. Truncated ALK derived from chromosomal translocation t(2;5)(p23;q35) binds to the SH3 domain of p85-PI3K.
Polgar D; Leisser C; Maier S; Strasser S; Rüger B; Dettke M; Khorchide M; Simonitsch I; Cerni C; Krupitza G
Mutat Res; 2005 Feb; 570(1):9-15. PubMed ID: 15680399
[TBL] [Abstract][Full Text] [Related]
28. Further demonstration of the diversity of chromosomal changes involving 2p23 in ALK-positive lymphoma: 2 cases expressing ALK kinase fused to CLTCL (clathrin chain polypeptide-like).
Touriol C; Greenland C; Lamant L; Pulford K; Bernard F; Rousset T; Mason DY; Delsol G
Blood; 2000 May; 95(10):3204-7. PubMed ID: 10807789
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of tyrosine kinase activity induces caspase-dependent apoptosis in anaplastic large cell lymphoma with NPM-ALK (p80) fusion protein.
Ergin M; Denning MF; Izban KF; Amin HM; Martinez RL; Saeed S; Alkan S
Exp Hematol; 2001 Sep; 29(9):1082-90. PubMed ID: 11532349
[TBL] [Abstract][Full Text] [Related]
30. The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements.
Pittaluga S; Wlodarska I; Pulford K; Campo E; Morris SW; Van den Berghe H; De Wolf-Peeters C
Am J Pathol; 1997 Aug; 151(2):343-51. PubMed ID: 9250148
[TBL] [Abstract][Full Text] [Related]
31. Molecular analysis of the NPM-ALK rearrangement in Hodgkin's disease.
Xerri L; Parc P; Hassoun J; Birnbaum D
J Pathol; 1996 Feb; 178(2):128-32. PubMed ID: 8683377
[TBL] [Abstract][Full Text] [Related]
32. The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner.
Hsu FY; Johnston PB; Burke KA; Zhao Y
Cancer Res; 2006 Sep; 66(18):9002-8. PubMed ID: 16982741
[TBL] [Abstract][Full Text] [Related]
33. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions.
Elmberger PG; Lozano MD; Weisenburger DD; Sanger W; Chan WC
Blood; 1995 Nov; 86(9):3517-21. PubMed ID: 7579458
[TBL] [Abstract][Full Text] [Related]
34. Model of inhibition of the NPM-ALK kinase activity by herbimycin A.
Turturro F; Arnold MD; Frist AY; Pulford K
Clin Cancer Res; 2002 Jan; 8(1):240-5. PubMed ID: 11801565
[TBL] [Abstract][Full Text] [Related]
35. Identification of anaplastic lymphoma kinase variant translocations using 5'RACE.
Hernández L; Campo E
Methods Mol Med; 2005; 115():295-314. PubMed ID: 15998975
[TBL] [Abstract][Full Text] [Related]
36. Differential expression of BCL-2 family proteins in ALK-positive and ALK-negative anaplastic large cell lymphoma of T/null-cell lineage.
Rassidakis GZ; Sarris AH; Herling M; Ford RJ; Cabanillas F; McDonnell TJ; Medeiros LJ
Am J Pathol; 2001 Aug; 159(2):527-35. PubMed ID: 11485911
[TBL] [Abstract][Full Text] [Related]
37. [Overexpression of NPM-ALK induces different types of malignant lymphomas in IL-9 transgenic mice].
Merz H; Lange K; Nadrowitz R; Uckert W; Blankenstein T; Feller AC
Verh Dtsch Ges Pathol; 2003; 87():224-31. PubMed ID: 16888916
[TBL] [Abstract][Full Text] [Related]
38. Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17-demethoxygeldanamycin.
Bonvini P; Gastaldi T; Falini B; Rosolen A
Cancer Res; 2002 Mar; 62(5):1559-66. PubMed ID: 11888936
[TBL] [Abstract][Full Text] [Related]
39. Detection of normal and chimeric nucleophosmin in human cells.
Cordell JL; Pulford KA; Bigerna B; Roncador G; Banham A; Colombo E; Pelicci PG; Mason DY; Falini B
Blood; 1999 Jan; 93(2):632-42. PubMed ID: 9885226
[TBL] [Abstract][Full Text] [Related]
40. Biochemical differences between SUDHL-1 and KARPAS 299 cells derived from t(2;5)-positive anaplastic large cell lymphoma are responsible for the different sensitivity to the antiproliferative effect of p27(Kip1).
Turturro F; Frist AY; Arnold MD; Seth P; Pulford K
Oncogene; 2001 Jul; 20(33):4466-75. PubMed ID: 11494142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]